Fiorenza Santamaria | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis	TARGETED ONCOLOGY	2024
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset	ESMO OPEN	2024
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2024
Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis	CURRENT ONCOLOGY	2024
529P Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study	ANNALS OF ONCOLOGY	2024
73P Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective “ReTrITA” study	ANNALS OF ONCOLOGY	2024
Survival benefit with regorafenib and/or trifluridine/tipiracil sequencing to rechallenge with anti-EGFR-based third-line regimens in metastatic colorectal cancer: A multicenter retrospective real-world subgroups comparison	JOURNAL OF CLINICAL ONCOLOGY	2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study	CURRENT ONCOLOGY	2024
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study	JOURNAL OF CLINICAL ONCOLOGY	2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study	CURRENT ONCOLOGY	2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis	CANCERS	2023
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study	ANNALS OF ONCOLOGY	2023
P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis	ANNALS OF ONCOLOGY	2023
P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis	ANNALS OF ONCOLOGY	2023
Comparative Analysis of Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-Life Multicenter Retrospective Study	TUMORI	2022
398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment	ANNALS OF ONCOLOGY	2022